Hyperthermic IP therapy.

Trial name or title	Secondary Debulking Surgery +/‐ Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer (NCT00426257)
Methods	This phase III randomised, open‐label trial compares a single intraperitoneal perfusion of chemotherapy under hyperthermic conditions immediately after interval debulking surgery (OVHIPEC) versus no intraperitoneal therapy
Participants	Women with stage III ovarian, peritoneal or tubal carcinoma who are eligible for interval debulking surgery either following primary chemotherapy or following incomplete primary debulking and chemotherapy. Participants must be between 18 and 76 yr old and not have had relevant competing previous malignancies. Estimated enrolment = 280 women
Interventions	Arm 1: Secondary debulking surgery with hyperthermic intraperitoneal chemotherapy (cisplatin 100 mg/m2 at the end of surgery) Arm 2: Secondary debulking surgery
Outcomes	Primary: duration of recurrence free survival following completion of treatment. Secondary: toxicity and morbidity, quality of life, tumour response following treatment and overall survival
Starting date	Feb 2007
Contact information	Willemien J van Driel, MD Ph: +31 20 512 2975 Email: w.v.driel@nki.nl
Notes	Estimated completion date 2013